Vivimed Labs Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: January 12, 2025, 8:52 pm

Market Cap	41.0 Cr.
Current Price	4.95
High / Low	/
Stock P/E
Book Value	3.12
Dividend Yield	0.00 %
ROCE	9.38 %
ROE	233 %
Face Value	2.00
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Vivimed Labs Ltd

Competitors of Vivimed Labs Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.27 Cr.	3.80	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	50.4 Cr.	67.9	94.9/30.8	17.1	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	41.3 Cr.	28.2	29.0/8.74	42.2	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	68.2 Cr.	90.5	155/81.2	11.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,201.67 Cr	1,062.38		42.63	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Vivimed Labs Ltd

Quarterly Result

Metric	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Sales	278	39	65	54	57	61	50	44	56	37	35	34	41
Expenses	300	55	54	65	64	62	59	54	61	201	36	40	40
Operating Profit	-22	-16	11	-10	-7	-1	-9	-9	-5	-164	-0	-6	1
OPM %	-8%	-42%	17%	-19%	-13%	-2%	-17%	-21%	-9%	-444%	-1%	-18%	3%
Other Income	4	2	1	0	-0	1	0	0	0	1	0	2	0
Interest	16	9	10	9	12	10	9	9	9	9	11	12	13
Depreciation	17	4	5	4	4	5	4	4	4	96	5	5	5
Profit before tax	-50	-28	-2	-23	-24	-16	-22	-22	-18	-268	-16	-20	-17
Tax %	-1%	-2%	0%	0%	0%	18%	-0%	0%	0%	-1%	0%	0%	-3%
Net Profit	-50	-27	-2	-23	-24	-18	-22	-22	-18	-266	-16	-20	-16
EPS in Rs	-5.98	-3.31	-0.28	-2.81	-2.86	-2.21	-2.68	-2.66	-2.21	-32.08	-1.88	-2.45	-1.94

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	668	1,109	1,351	1,380	1,346	1,462	1,186	1,315	1,059	861	237	187	147
Expenses	538	916	1,139	1,156	1,111	1,057	971	1,135	1,049	830	245	374	317
Operating Profit	130	193	212	224	234	404	215	180	10	32	-8	-187	-169
OPM %	20%	17%	16%	16%	17%	28%	18%	14%	1%	4%	-3%	-100%	-115%
Other Income	3	12	8	6	11	8	10	23	8	10	1	1	3
Interest	28	48	67	86	84	68	82	70	61	56	40	36	44
Depreciation	27	59	66	66	61	58	56	67	67	56	18	108	110
Profit before tax	78	98	87	78	100	286	86	66	-109	-70	-65	-331	-321
Tax %	19%	15%	24%	7%	16%	25%	11%	13%	-0%	3%	4%	-1%
Net Profit	63	84	66	72	84	214	76	57	-109	-72	-68	-329	-318
EPS in Rs	9.06	10.41	8.20	8.90	10.33	26.41	9.44	6.95	-13.16	-8.67	-8.16	-39.62	-38.35
Dividend Payout %	7%	6%	7%	0%	0%	2%	4%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2012-2013	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023
YoY Net Profit Growth (%)	33.33%	-21.43%	9.09%	16.67%	154.76%	-64.49%	-25.00%	-291.23%	33.94%	5.56%	-383.82%
Change in YoY Net Profit Growth (%)	0.00%	-54.76%	30.52%	7.58%	138.10%	-219.25%	39.49%	-266.23%	325.17%	-28.39%	-389.38%

Vivimed Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: January 13, 2025, 2:32 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	16	16	16	16	16	17	17	17	17	17	17	17	17
Reserves	429	480	479	505	718	885	602	493	415	348	23	-22	-42
Borrowings	729	958	1,076	1,015	1,011	1,149	1,280	1,268	326	359	379	377	376
Other Liabilities	402	404	327	519	317	343	431	432	532	543	658	579	593
Total Liabilities	1,577	1,858	1,898	2,055	2,062	2,394	2,329	2,210	1,289	1,266	1,076	950	943
Fixed Assets	709	808	813	814	879	1,035	965	1,045	502	520	436	418	411
CWIP	27	38	90	94	76	65	122	89	60	40	21	21	23
Investments	0	0	3	3	3	3	3	86	199	199	199	168	168
Other Assets	840	1,011	992	1,144	1,104	1,290	1,239	990	529	507	421	343	340
Total Assets	1,577	1,858	1,898	2,055	2,062	2,394	2,329	2,210	1,289	1,266	1,076	950	943

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Free Cash Flow	130.00	-536.00	-746.00	223.00	233.00	403.00	214.00	179.00	9.00	-294.00	-367.00	-566.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	121	101	94	87	88	50	85	99	86	46	134	150
Inventory Days	268	247	249	244	294	329	411	397	396	263	573	216
Days Payable	170	118	106	107	98	122	154	207	179	35	100	93
Cash Conversion Cycle	220	230	237	224	285	258	342	288	303	274	607	273
Working Capital Days	208	161	159	146	169	151	239	161	216	190	653	588
ROCE %	14%	13%	12%	11%	12%	22%	9%	7%	-3%	-1%	-3%	-52%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Promoters	28.57%	28.57%	28.57%	28.57%	21.98%	20.96%	20.96%	20.96%	20.94%	20.94%	20.94%	20.94%
FIIs	3.10%	2.66%	1.85%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
Government	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
Public	68.21%	68.65%	69.47%	69.67%	76.27%	77.29%	77.28%	77.29%	77.30%	77.30%	77.29%	77.30%
No. of Shareholders	37,989	51,963	50,928	52,074	53,110	53,376	52,398	51,026	50,683	49,503	49,038	49,027

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	-39.62	-8.16	-8.67	-13.16	6.95
Diluted EPS (Rs.)	-39.62	-7.92	-8.42	-12.77	6.67
Cash EPS (Rs.)	-26.55	-5.95	-1.98	-5.09	15.04
Book Value[Excl.RevalReserv]/Share (Rs.)	0.17	39.35	47.47	56.85	70.35
Book Value[Incl.RevalReserv]/Share (Rs.)	4.75	43.93	52.05	61.43	74.96
Revenue From Operations / Share (Rs.)	22.57	28.62	103.90	127.70	159.37
PBDIT / Share (Rs.)	-22.47	-0.81	4.77	1.97	24.25
PBIT / Share (Rs.)	-35.55	-3.02	-1.93	-6.10	16.15
PBT / Share (Rs.)	-39.88	-7.82	-8.43	-13.20	8.00
Net Profit / Share (Rs.)	-39.62	-8.16	-8.67	-13.16	6.95
NP After MI And SOA / Share (Rs.)	-39.62	-8.16	-8.67	-13.16	6.95
PBDIT Margin (%)	-99.59	-2.86	4.58	1.54	15.21
PBIT Margin (%)	-157.53	-10.56	-1.85	-4.77	10.13
PBT Margin (%)	-176.72	-27.32	-8.10	-10.33	5.02
Net Profit Margin (%)	-175.59	-28.50	-8.34	-10.30	4.36
NP After MI And SOA Margin (%)	-175.59	-28.50	-8.34	-10.30	4.36
Return on Networth / Equity (%)	-23087.35	-20.73	-18.26	-23.14	9.88
Return on Capital Employeed (%)	-52.25	-2.80	-1.68	-3.51	9.25
Return On Assets (%)	-33.24	-5.34	-5.57	-4.93	2.46
Long Term Debt / Equity (X)	43.79	0.18	0.14	0.99	0.73
Total Debt / Equity (X)	266.03	1.10	0.64	1.89	1.30
Asset Turnover Ratio (%)	0.16	0.18	0.12	0.16	0.14
Current Ratio (X)	0.78	1.36	1.55	1.27	1.38
Quick Ratio (X)	0.59	0.71	0.80	0.61	0.75
Inventory Turnover Ratio (X)	1.17	0.57	0.24	0.37	0.31
Dividend Payout Ratio (NP) (%)	0.00	0.00	0.00	0.00	574.49
Dividend Payout Ratio (CP) (%)	0.00	0.00	0.00	0.00	265.44
Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	-474.49
Cash Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	-165.44
Interest Coverage Ratio (X)	-5.19	-0.17	0.73	0.27	2.97
Interest Coverage Ratio (Post Tax) (X)	-8.15	-0.70	-0.33	-0.85	1.85
Enterprise Value (Cr.)	430.11	471.51	378.03	898.62	854.91
EV / Net Operating Revenue (X)	2.30	1.99	0.43	0.84	0.65
EV / EBITDA (X)	-2.31	-69.44	9.57	54.91	4.27
MarketCap / Net Operating Revenue (X)	0.29	0.50	0.15	0.05	0.14
Retention Ratios (%)	0.00	0.00	0.00	0.00	-474.49
Price / BV (X)	38.87	0.36	0.33	0.12	0.33
Price / Net Operating Revenue (X)	0.29	0.50	0.15	0.05	0.14
EarningsYield	-5.94	-0.56	-0.54	-1.81	0.29

After reviewing the key financial ratios for Vivimed Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 23, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 22) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 5. It has decreased from -8.16 (Mar 22) to -39.62, marking a decrease of 31.46.
For Diluted EPS (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 5. It has decreased from -7.92 (Mar 22) to -39.62, marking a decrease of 31.70.
For Cash EPS (Rs.), as of Mar 23, the value is -26.55. This value is below the healthy minimum of 3. It has decreased from -5.95 (Mar 22) to -26.55, marking a decrease of 20.60.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 0.17. It has decreased from 39.35 (Mar 22) to 0.17, marking a decrease of 39.18.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 4.75. It has decreased from 43.93 (Mar 22) to 4.75, marking a decrease of 39.18.
For Revenue From Operations / Share (Rs.), as of Mar 23, the value is 22.57. It has decreased from 28.62 (Mar 22) to 22.57, marking a decrease of 6.05.
For PBDIT / Share (Rs.), as of Mar 23, the value is -22.47. This value is below the healthy minimum of 2. It has decreased from -0.81 (Mar 22) to -22.47, marking a decrease of 21.66.
For PBIT / Share (Rs.), as of Mar 23, the value is -35.55. This value is below the healthy minimum of 0. It has decreased from -3.02 (Mar 22) to -35.55, marking a decrease of 32.53.
For PBT / Share (Rs.), as of Mar 23, the value is -39.88. This value is below the healthy minimum of 0. It has decreased from -7.82 (Mar 22) to -39.88, marking a decrease of 32.06.
For Net Profit / Share (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 2. It has decreased from -8.16 (Mar 22) to -39.62, marking a decrease of 31.46.
For NP After MI And SOA / Share (Rs.), as of Mar 23, the value is -39.62. This value is below the healthy minimum of 2. It has decreased from -8.16 (Mar 22) to -39.62, marking a decrease of 31.46.
For PBDIT Margin (%), as of Mar 23, the value is -99.59. This value is below the healthy minimum of 10. It has decreased from -2.86 (Mar 22) to -99.59, marking a decrease of 96.73.
For PBIT Margin (%), as of Mar 23, the value is -157.53. This value is below the healthy minimum of 10. It has decreased from -10.56 (Mar 22) to -157.53, marking a decrease of 146.97.
For PBT Margin (%), as of Mar 23, the value is -176.72. This value is below the healthy minimum of 10. It has decreased from -27.32 (Mar 22) to -176.72, marking a decrease of 149.40.
For Net Profit Margin (%), as of Mar 23, the value is -175.59. This value is below the healthy minimum of 5. It has decreased from -28.50 (Mar 22) to -175.59, marking a decrease of 147.09.
For NP After MI And SOA Margin (%), as of Mar 23, the value is -175.59. This value is below the healthy minimum of 8. It has decreased from -28.50 (Mar 22) to -175.59, marking a decrease of 147.09.
For Return on Networth / Equity (%), as of Mar 23, the value is -23,087.35. This value is below the healthy minimum of 15. It has decreased from -20.73 (Mar 22) to -23,087.35, marking a decrease of 23,066.62.
For Return on Capital Employeed (%), as of Mar 23, the value is -52.25. This value is below the healthy minimum of 10. It has decreased from -2.80 (Mar 22) to -52.25, marking a decrease of 49.45.
For Return On Assets (%), as of Mar 23, the value is -33.24. This value is below the healthy minimum of 5. It has decreased from -5.34 (Mar 22) to -33.24, marking a decrease of 27.90.
For Long Term Debt / Equity (X), as of Mar 23, the value is 43.79. This value exceeds the healthy maximum of 1. It has increased from 0.18 (Mar 22) to 43.79, marking an increase of 43.61.
For Total Debt / Equity (X), as of Mar 23, the value is 266.03. This value exceeds the healthy maximum of 1. It has increased from 1.10 (Mar 22) to 266.03, marking an increase of 264.93.
For Asset Turnover Ratio (%), as of Mar 23, the value is 0.16. It has decreased from 0.18 (Mar 22) to 0.16, marking a decrease of 0.02.
For Current Ratio (X), as of Mar 23, the value is 0.78. This value is below the healthy minimum of 1.5. It has decreased from 1.36 (Mar 22) to 0.78, marking a decrease of 0.58.
For Quick Ratio (X), as of Mar 23, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 22) to 0.59, marking a decrease of 0.12.
For Inventory Turnover Ratio (X), as of Mar 23, the value is 1.17. This value is below the healthy minimum of 4. It has increased from 0.57 (Mar 22) to 1.17, marking an increase of 0.60.
For Dividend Payout Ratio (NP) (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 22) which recorded 0.00.
For Dividend Payout Ratio (CP) (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 22) which recorded 0.00.
For Earning Retention Ratio (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 22) which recorded 0.00.
For Cash Earning Retention Ratio (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 22) which recorded 0.00.
For Interest Coverage Ratio (X), as of Mar 23, the value is -5.19. This value is below the healthy minimum of 3. It has decreased from -0.17 (Mar 22) to -5.19, marking a decrease of 5.02.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 23, the value is -8.15. This value is below the healthy minimum of 3. It has decreased from -0.70 (Mar 22) to -8.15, marking a decrease of 7.45.
For Enterprise Value (Cr.), as of Mar 23, the value is 430.11. It has decreased from 471.51 (Mar 22) to 430.11, marking a decrease of 41.40.
For EV / Net Operating Revenue (X), as of Mar 23, the value is 2.30. This value is within the healthy range. It has increased from 1.99 (Mar 22) to 2.30, marking an increase of 0.31.
For EV / EBITDA (X), as of Mar 23, the value is -2.31. This value is below the healthy minimum of 5. It has increased from -69.44 (Mar 22) to -2.31, marking an increase of 67.13.
For MarketCap / Net Operating Revenue (X), as of Mar 23, the value is 0.29. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 22) to 0.29, marking a decrease of 0.21.
For Retention Ratios (%), as of Mar 23, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 22) which recorded 0.00.
For Price / BV (X), as of Mar 23, the value is 38.87. This value exceeds the healthy maximum of 3. It has increased from 0.36 (Mar 22) to 38.87, marking an increase of 38.51.
For Price / Net Operating Revenue (X), as of Mar 23, the value is 0.29. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 22) to 0.29, marking a decrease of 0.21.
For EarningsYield, as of Mar 23, the value is -5.94. This value is below the healthy minimum of 5. It has decreased from -0.56 (Mar 22) to -5.94, marking a decrease of 5.38.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Vivimed Labs Ltd as of February 24, 2025 is: ₹88.98

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 24, 2025, Vivimed Labs Ltd is Undervalued by 1,697.58% compared to the current share price ₹4.95

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Vivimed Labs Ltd as of February 24, 2025 is: 46.31

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 24, 2025, Vivimed Labs Ltd is Undervalued by 835.56% compared to the current share price ₹4.95

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -47.96%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
	The stock has a low average ROCE of 3.42%, which may not be favorable. The stock has a high average Working Capital Days of 253.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 295.08, which may not be favorable. The company has higher borrowings (792.54) compared to reserves (408.69), which may suggest financial risk. The company has not shown consistent growth in sales (162.15) and profit (-1.31).

Strength

Weakness

The stock has a low average ROCE of 3.42%, which may not be favorable.
The stock has a high average Working Capital Days of 253.42, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 295.08, which may not be favorable.
The company has higher borrowings (792.54) compared to reserves (408.69), which may suggest financial risk.
The company has not shown consistent growth in sales (162.15) and profit (-1.31).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vivimed Labs Ltd:
1. Net Profit Margin: -175.59%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -52.25% (Industry Average ROCE: 16.18%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -23087.35% (Industry Average ROE: 16.43%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -8.15
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.59
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 42.63)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 266.03
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Vivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L02411KA1988PLC009465 and registration number is 009465. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 136.80 Cr. and Equity Capital is Rs. 16.58 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Plot No. 78/A, Kolhar Industrial Area, Bidar Karnataka 585403	yugandhar.kopparthi@vivimedlabs.com www.vivimedlabs.com

Management
Name	Position Held
Dr. Manohar Rao Varalwar	Chairman & Wholetime Director
Mr. Santosh Varalwar	Managing Director
Mr. Sandeep Varalwar	Whole Time Director
Ms. Aparna Bidarkar	Independent Director
Mr. Subbarathnamma Palepu	Independent Director
Mr. Jarugula Siva Prasad	Independent Director

FAQ

What is the latest intrinsic value of Vivimed Labs Ltd?

The latest intrinsic value of Vivimed Labs Ltd as on 04 February 2025 is ₹88.98, which is 1697.58% higher than the current market price of ₹4.95, indicating the stock is undervalued by 1697.58%. The stock has a market capitalization of 41.0 Cr. and recorded a high/low of / during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹-42 Cr and total liabilities of 943 Cr.

What is the Market Cap of Vivimed Labs Ltd?

The Market Cap of Vivimed Labs Ltd is 41.0 Cr..

What is the current Stock Price of Vivimed Labs Ltd as on 04 February 2025?

The current stock price of Vivimed Labs Ltd as on 04 February 2025 is 4.95.

What is the High / Low of Vivimed Labs Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Vivimed Labs Ltd stocks is /.

What is the Stock P/E of Vivimed Labs Ltd?

The Stock P/E of Vivimed Labs Ltd is .

What is the Book Value of Vivimed Labs Ltd?

The Book Value of Vivimed Labs Ltd is 3.12.

What is the Dividend Yield of Vivimed Labs Ltd?

The Dividend Yield of Vivimed Labs Ltd is 0.00 %.

What is the ROCE of Vivimed Labs Ltd?

The ROCE of Vivimed Labs Ltd is 9.38 %.

What is the ROE of Vivimed Labs Ltd?

The ROE of Vivimed Labs Ltd is 233 %.

What is the Face Value of Vivimed Labs Ltd?

The Face Value of Vivimed Labs Ltd is 2.00.